Ablynx's vobarilizumab achieves positive top-line results as RA monotherapy

7 July 2016

Belgian drug developer Ablynx (Euronext Brussels: ABLX) has announced positive top-line results of its Phase IIb trial of vobarilizumab (ALX-0061) as a monotherapy in rheumatoid arthritis (RA), with the news pushing the firm's shares 14% higher to 13.14 euros in morning trading.

The study of Ablynx’s anti-IL-6R Nanobody comprised of patients with moderately to severely active RA who are intolerant to methotrexate or for whom continued methotrexate (MTX) treatment is inappropriate.

The objective of the study was to explore the efficacy and safety of various dose regimens for vobarilizumab monotherapy to guide further clinical development, and to obtain parallel descriptive information for tocilizumab in the same clinical trial RA population.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK